Originally from Halmstad, Sweden, Christer Rosén is the primary founder and Chairman & CEO of Jupiter Neurosciences, Inc.. His background and education as a programmer and system analyst gives him a solution minded mentality and an expert in building companies with strong and dedicated people. He started his first company at the age of 17, a discotheque opened only on the weekends not to disturb study times. After college he started a software consulting company as well as buying a few restaurants and a hotel continuing the involvement in the entertainment business. In 1983, Mr. Rosén and his family decided to leave Sweden and moved to Florida in search of new ventures to be involved in. After purchasing a Jeep Wrangler, he invented the “Soundbar”, speaker system fastened to the overheard roll bar, became a Jeep supplier and received supplier of the year awards in 1995 and 1996. The company, Top Source Technologies where he was President, went public on the American Stock Exchange and was later bought by a PE firm. Afterwards, Mr. Rosén started EffRx Pharmaceuticals in 1997, where he served as Chairman & CEO for 17 years.. EffRx was started as a vitamin company, but with the addition of Marshall Hayward, Jupiter Neurosciences CSO, invented, developed and received FDA and EU approvals of a drug treating osteoporosis, Binosto®. Binosto® is distributed in several parts of the world and gave Mr. Rosén a successful and full insight in all the aspects of pharmaceutical development, regulatory paths and distribution.

Marshall Hayward is the Chief Scientific Officer at Jupiter Neurosciences, Inc. Between 2002-2013, Dr. Hayward served as Chief Scientific Officer at Effrx Pharmaceuticals where he was instrumental in all aspects of the development and approvals of the Binosto® product. He also served as Vice President of Business Development for Hurley Consulting Associates, LTD., a specialist pharmaceutical consulting firm, and was previously Director of New Business Development at Rhoda Pharmaceutical Ingredients. Dr. Hayward was also the Director and Vice President of Analgesics Research and Development at SmithKline Beecham (UK). He was a senior scientist in wound healing research and development at Johnson & Johnson. His pharmaceutical experience began at Ayerst Laboratories Research (later Wyeth), responsible for metabolic bone disease research. Dr. Hayward received a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign and did postdoctoral work there in molecular biology. His undergraduate degree is a B.S. (Biochemistry with High Honor) from the Honors College of Michigan State University. In total, Dr. Hayward has over 30 years of industry R&D experience.

Alison D. Silva is the President, Chief Executive Officer and a Director of Cotinga Pharmaceuticals Inc., formerly Critical Outcome Technologies, Inc. Previously, she was a co‐founder, Executive Vice President and Chief Operating Officer at Synlogic, Inc. where she lead the regulatory strategy, drug development, and operational aspects of the company’s focus on the discovery and development of engineered therapeutic probiotics. Alison is also a co‐founder of The Orphan Group, a specialty consulting company focused on assisting companies with developing and implementing their orphan drug strategy and product lifecycle management.

Alison previously held the position of Chief Operating Officer at SLA Pharma, a GI‐oncology focused biotech company, where she was responsible for heading up U.S. corporate and clinical operations for their pipeline of orphan drug candidates. Prior to joining SLA Pharma, Alison was Vice President of Drug Development at Marina Biotech through its acquisition of Cequent Pharmaceuticals in 2010, where she held the same role since 2007. Alison began her career in drug development in clinical operations with various positions at Pfizer, Massachusetts General Hospital, and the University of Massachusetts. Alison obtained her undergraduate degree from Clark University and her graduate degree from the University of Massachusetts Medical Center

Nicholas H. Hemmerly has been a Managing Partner and Head of Investment Banking for Bridgeway Capital Partners LLC (“Bridgeway”) since February 2020. Mr. Hemmerly has over 18 years of investment banking experience with broad transactional experience having completed approximately $25 billion of debt and equity transactions. Prior to joining Bridgeway from March 2016 to February 2020, Mr. Hemmerly was the Director, Head of Life Sciences at PricewaterhouseCoopers LLC (“PwC”) where he led U.S. M&A and capital raising in the life sciences space with a focus on specialty and generic pharmaceuticals as well as healthcare consumer products and contract manufacturing. Prior to PwC from June 2014 to March 2016, Mr. Hemmerly was a Vice President at Jefferies LLC with a focus on executing M&A and financing transactions within the pharmaceutical and life sciences sectors. Prior experience includes investment banking roles in JPMorgan Chase & Co.’s Healthcare Group as well as JMP Securities LLC’s Healthcare Group. Mr. Hemmerly began his investment banking career as an analyst with Wachovia Securities. During his career, Mr. Hemmerly has completed over six billion dollars in M&A and capital raising transactions.

Experienced life science executive and entrepreneur with demonstrated ability to lead cross functional team of experts to develop emerging healthcare technologies. Ability to leverage broad managerial, operational, research and financial experience to achieve results in organizations backed by private investors, venture capital, private equity and/or corporate industry partners.

For over 25 years, Allison W. Brady has been a passionate fundraiser and advocate for rare diseases medical research and patients.

She serves on the board of Gene Spotlight, Inc., a non-profit dedicated to raising money to sponsor medical research for rare diseases. She has organized fundraising events for the charity through Give Miami Day, De Beers (jewelry store), Ann Taylor (clothing store), online charity auctions with Miley Cyrus, Keith Urban, Miami Marlins via CharityBuzz to raise funds for Gene Spotlight. She co-runs an annual bike team for Team Gene Spotlight to raise funds for the Million Dollar Bike Ride with Penn Medicine to fund research grants. Gene Spotlight is the largest outside investor in Jupiter orphan Therapeutics, Inc.

Her fundraising efforts for rare diseases began with gala events she organized called “Songs for Sophia” with performances by opera’s finest including Placido Domingo, Denyce Graves, Bryn Terfel, and Frederica von Stade. The money raised from those events supported medical research for a rare bone disease known as FOP.

She also worked with the press outreach, including having the Associated Press cover these events, which led to them following the scientific and medical progress of FOP for over a decade as new techniques using shark cartilage were developed and the FOP gene was discovered at CHOP by Dr. Fred Kaplan at UPENN. In part, due to her success in fundraising and awareness of FOP, in 2007, Allison was the sole recipient of the University of Pennsylvania’s Young Alumni of the Year Award.

She actively supports several other medical based charities including EveryLife Foundation for Rare Diseases, Jackson Health Foundation, Penn Medicine, Mount Sinai Miami Beach, Mount Sinai New York City, Kids Hear Now, Nicklaus Children’s Hospital, Sabrina Cohen Foundation, United HomeCare Services, and more.